Onconetix (NASDAQ:ONCO) Rating Increased to Hold at Wall Street Zen

Onconetix (NASDAQ:ONCO) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a research note issued on Saturday.

Onconetix Stock Performance

ONCO stock opened at $4.73 on Friday. Onconetix has a 52-week low of $4.27 and a 52-week high of $1,190.00. The stock’s 50 day moving average is $6.11 and its two-hundred day moving average is $25.39.

Onconetix (NASDAQ:ONCO) last posted its quarterly earnings data on Thursday, June 12th. The company reported $21.25 earnings per share (EPS) for the quarter. The business had revenue of $0.10 million for the quarter.

Institutional Investors Weigh In On Onconetix

A hedge fund recently bought a new stake in Onconetix stock. Geode Capital Management LLC purchased a new stake in Onconetix, Inc. (NASDAQ:ONCO) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 55,418 shares of the company’s stock, valued at approximately $35,000. Geode Capital Management LLC owned about 0.67% of Onconetix at the end of the most recent quarter. 23.89% of the stock is currently owned by institutional investors and hedge funds.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.